Across TCGA pan-cancer cohorts, H2AC1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated H2AC1 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher H2AC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H2AC1 expression acts as an unfavorable survival marker.
LUSC, SKCM, and GBM are the cancer types where H2AC1 Mutation most reproducibly stratifies survival.